SCHEMBL2124366

SCHEMBL2124366

CC(c1ccccc1)n1ccc2cc(Br)ccc2c1=O

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DPP4 P27487 1/20 0.39
BRD4 O60885 2/20 0.38
TDP2 O95551 1/20 0.37
CDC25B P30305 1/20 0.37
CASP6 P55212 1/20 0.37
PPP1CA P62136 1/20 0.37
MEN1 O00255 4/20 0.36
KMT2A Q03164 4/20 0.36
PTGS2 P35354 1/20 0.36
MAPT P10636 1/20 0.36
MET P08581 1/20 0.35
RXFP1 Q9HBX9 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
ATM Q13315 1/20 0.35
POLB P06746 1/20 0.35
DNMT3A Q9Y6K1 1/20 0.34
ALDH1A1 P00352 1/20 0.34
HPGD P15428 1/20 0.34
HTR2A P28223 1/20 0.34
HTR2C P28335 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29136061 0.86 ALDH1A1 (0.38) MEN1KMT2APTGS2MAPTRXFP1
SCHEMBL29779156 0.86 ALDH1A1 (0.38) MEN1KMT2APTGS2MAPTRXFP1
SCHEMBL20495377 0.84 BRD4 (0.41) BRD4MEN1KMT2APTGS2MET
SCHEMBL2122301 0.83 APLNR (0.37) DPP4TDP2CDC25BCASP6PPP1CA
SCHEMBL20495345 0.82 HTR2A (0.42) BRD4MEN1KMT2AMETALDH1A1
SCHEMBL20495346 0.82 HTR2A (0.42) BRD4MEN1KMT2AMETALDH1A1
SCHEMBL1500297 0.82 HTR2A (0.39) DPP4MAPTRXFP1ALDH1A1HTR2A
SCHEMBL2627973 0.80 CA1 (0.37) BRD4MEN1KMT2AMETALDH1A1
SCHEMBL582559 0.80 TDP1 (0.40) DPP4MEN1KMT2AHTR2AHTR2C
SCHEMBL582152 0.77 HTR2A (0.46) DPP4TDP2CDC25BCASP6PPP1CA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8802064-B2 Inhibitors of fatty acid amide hydrolase INFINITY PHARMACEUTICALS, INC. (US) 2014-08-12 US disclosed
EP-2416660-B1 INHIBITORS OF FATTY ACID AMIDE HYDROLASE INFINITY PHARMACEUTICALS INC (US) 2014-07-02 EP disclosed
US-20130345173-A1 INHIBITORS OF FATTY ACID AMIDE HYDROLASE INFINITY PHARMACEUTICALS, INC. (US) 2013-12-26 US disclosed
US-8546564-B2 Inhibitors of fatty acid amide hydrolase INFINITY PHARMACEUTICALS, INC. (US) 2013-10-01 US disclosed
US-20120094957-A1 INHIBITORS OF FATTY ACID AMIDE HYDROLASE INFINITY PHARMACEUTICALS INC. 2012-04-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130345173-A1 INHIBITORS OF FATTY ACID AMIDE HYDROLASE FAAH, FAAH2, FFAR3 DPP4 1158/4885BRD4 2355/4885TDP2 2809/4885
US-20120094957-A1 INHIBITORS OF FATTY ACID AMIDE HYDROLASE FAAH, FAAH2, FFAR3 DPP4 1072/4885BRD4 2282/4885TDP2 3060/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.